Lombard Odier Asset Management Europe Ltd Acquires New Stake in Stryker Corporation $SYK

Lombard Odier Asset Management Europe Ltd bought a new position in shares of Stryker Corporation (NYSE:SYK) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 1,656 shares of the medical technology company’s stock, valued at approximately $521,000.

A number of other institutional investors have also added to or reduced their stakes in SYK. Varma Mutual Pension Insurance Co boosted its holdings in shares of Stryker by 10.5% during the fourth quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company’s stock valued at $18,842,000 after acquiring an additional 5,100 shares during the period. QRG Capital Management Inc. increased its holdings in shares of Stryker by 7.4% in the 4th quarter. QRG Capital Management Inc. now owns 60,548 shares of the medical technology company’s stock worth $21,281,000 after acquiring an additional 4,186 shares during the period. Swedbank AB lifted its position in Stryker by 6.6% in the 4th quarter. Swedbank AB now owns 129,027 shares of the medical technology company’s stock valued at $45,349,000 after purchasing an additional 7,934 shares during the last quarter. Crossmark Global Holdings Inc. lifted its position in Stryker by 31.1% in the 4th quarter. Crossmark Global Holdings Inc. now owns 26,820 shares of the medical technology company’s stock valued at $9,426,000 after purchasing an additional 6,367 shares during the last quarter. Finally, Royal Bank of Canada boosted its stake in Stryker by 6.5% during the 1st quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock valued at $1,075,552,000 after purchasing an additional 199,863 shares during the period. 77.09% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director Ronda E. Stryker sold 300,000 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the completion of the transaction, the director owned 2,301,375 shares in the company, valued at approximately $773,031,862.50. This trade represents a 11.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Debra King sold 826 shares of Stryker stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the transaction, the insider directly owned 6,210 shares in the company, valued at $2,088,423. This represents a 11.74% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 351,267 shares of company stock worth $118,197,701. Corporate insiders own 4.60% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on SYK shares. Evercore set a $350.00 price target on shares of Stryker in a research note on Monday, July 6th. Wolfe Research downgraded Stryker from an “outperform” rating to a “peer perform” rating in a research report on Thursday, August 13th. UBS Group assumed coverage on Stryker in a report on Tuesday, July 28th. They issued a “buy” rating and a $400.00 price objective for the company. BMO Capital Markets assumed coverage on Stryker in a research report on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 target price on the stock. Finally, Leerink Partners cut their target price on Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a research note on Friday, June 5th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and an average target price of $386.28.

Stryker Price Performance

NYSE SYK opened at $331.32 on Friday. The firm has a market capitalization of $127.08 billion, a PE ratio of 34.33, a P/E/G ratio of 2.05 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $396.86. The company’s 50 day simple moving average is $329.10 and its 200 day simple moving average is $331.47.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. During the same period last year, the firm earned $3.13 EPS. The firm’s revenue for the quarter was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities research analysts forecast that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio is presently 36.48%.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.